VIDEO: Therapies in the pipeline for multiple myeloma

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

For sure, there are several medication in clinical trials. For instance, there is another type of biospecific antibody targeting BCMA, but also, there are biospecific antibody, targeting a different antigen called FC receptor-like 5, or FCRL5, that gives us the map. Then there are different type from different companies, CAR-T therapies targeting the same antigen of Talquetamab, that is GPRC5D. Novel immunomodulatory drugs or cell modes are all seen clinical trials that are kind of the advanced type of immunomodulatory drug. And then saline x-ray is still not technically approved, and in clinical trial in different setting, is frontline or for relapse refractory patient. Except for like novel, more like preclinical studies, there are lots of ongoing or upcoming clinical trials that explore the different combinations, or what is the best combination in specific subset of patients, based on patient characteristic, age, for instance, or frailty, or disease characteristics such as chromosomal abnormalities or high risk features.